Related references
Note: Only part of the references are listed.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz et al.
LANCET (2023)
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Min Yan et al.
LANCET ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
B. Xu et al.
ANNALS OF ONCOLOGY (2022)
Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase II trial
X. Wang et al.
ANNALS OF ONCOLOGY (2022)
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
Xiaofan Wu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Resistance to Trastuzumab
Sneha Vivekanandhan et al.
CANCERS (2022)
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Ilana Schlam et al.
CANCERS (2022)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
Binghe Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Sarika Jain et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Mathilde Guerin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Nadia Harbeck et al.
LANCET ONCOLOGY (2016)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A. Hurvitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003
I. E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
Hilda Wong et al.
ONCOLOGIST (2011)
Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Andrew M. Wardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Shawn P. Fessler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Filippo Montemurro et al.
ONCOLOGIST (2006)
Role of exon-16-deleted HER2 in breast carcinomas
F Castiglioni et al.
ENDOCRINE-RELATED CANCER (2006)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
Share Paper
